07:52 AM EDT, 03/25/2026 (MT Newswires) -- NetraMark Holdings ( AINMF ) said Wednesday that it is collaborating with Italian company Fondazione per la Medicina Personalizzata (FMP) to analyze its ROME Phase II oncology trial dataset.

NetraMark ( AINMF ) will deploy its NetraAI platform to identify "clinically actionable" insights that may inform future precision-oncology strategies and clinical trial design.

The ROME trial is a phase 2 study comparing tailored treatment to standard of care. The study evaluated patients with advanced solid tumors progressing after one or two prior lines of therapy, guided by genomic profiling which analyzes a patient's tissue and blood to identify genetic mutations and alterations.

"NetraAI was built to reveal clinically meaningful structure within complex trial datasets by identifying compact, interpretable patient subpopulations where treatment effects become detectable," said Dr. Joseph Geraci, chief scientific and technology officer at NetraMark ( AINMF ).

"We are pleased to collaborate with FMP on the ROME program and apply this methodology to potentially produce insights that can be communicated clearly to clinical stakeholders and those responsible for translating findings into trial design, regulatory strategy, and patient care."